drugset / Trial / NCT03398720
Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors
Non-randomizedParallel-groupOpen-labelTreatment
Summary
HTI-1066 is a novel ADC being developed for the treatment of cancers in patients with overexpression of c-Met. This 2-part, Phase 1 study evaluates the safety the tolerability of HTI-1066 in subjects with advanced solid tumors.
Timeline
- Start
- 2017-12-31
- Primary completion
- 2018-12-31
- Completion
- 2019-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HTI-1066 | Unknown | — | — |